Advanced generation adenoviral vectors possess augmented gene transfer efficiency based upon coxsackie adenovirus receptor-independent cellular entry capacity

Victor Krasnykh, Igor Dmitriev, Jesus Gomez Navarro, Natalya Belousova, Elena Kashentseva, Jialing Xiang, Joanne T. Douglas, David T. Curiel

Research output: Contribution to journalReview articlepeer-review

81 Scopus citations

Abstract

Adenoviral (Ad) vectors have been widely used in the context of cancer gene therapy approaches. Their utility in these contexts, however, has frequently been limited by tumor cell resistance to Ad infection. The basis of this resistance has been defined recently as resulting from a deficiency of the primary adenovirus receptor, coxsackie adenovirus receptor. As a means to circumvent this limitation, a variety of tropism modification strategies have allowed coxsackie adenovirus receptor-independent gene delivery via the Ad vector. These advanced generation adenovirus vectors exhibit enhanced infectivity, which can allow direct therapeutic gain. Such vectors may allow improvements in efficacy in the context of ongoing human clinical gene therapy approaches for cancer.

Original languageEnglish
Pages (from-to)6784-6787
Number of pages4
JournalCancer research
Volume60
Issue number24
StatePublished - Dec 15 2000

Fingerprint Dive into the research topics of 'Advanced generation adenoviral vectors possess augmented gene transfer efficiency based upon coxsackie adenovirus receptor-independent cellular entry capacity'. Together they form a unique fingerprint.

Cite this